What is the translation of " VECTIBIX IN COMBINATION " in Slovenian?

• zdravilo vectibix v kombinaciji

Examples of using Vectibix in combination in English and their translations into Slovenian

Vectibix in combination with IFL.
Vectibix v kombinaciji z IFL.

Patients with ECOG 2 performance status treated with Vectibix in combination with chemotherapy.
Bolniki z zmogljivostnim stanjem 2 po ECOG, zdravljeni z zdravilom Vectibix v kombinaciji s kemoterapijo.

Vectibix in combination with bevacizumab and chemotherapy regimens.
Vectibix v kombinaciji z bevacizumabom in shemami kemoterapije.

Shortened progression free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy.
Krajši čas preživetja brez napredovanja in več smrti so opazili med bolniki, ki so dobivali zdravilo Vectibix v kombinaciji z bevacizumabom in kemoterapijo.

Therefore administration of Vectibix in combination with IFL should be avoided(see section 4.5).
Zato se je treba uporabi zdravila Vectibix v kombinaciji z IFL izogibati(glejte poglavje 4.5).

Another study in 80 previously untreated patients compared Vectibix and FOLFIRI with Vectibix in combination with FOLFOX.
V nadaljnji študiji so pri 80 predhodno nezdravljenih bolnikih zdravilo Vectibix, uporabljeno skupaj s kemoterapijo FOLFIRI, primerjali z zdravilom Vectibix, uporabljenim skupaj s kemoterapijo FOLFOX.

Vectibix in combination with irinotecan, bolus 5-fluorouracil, and leucovorin(IFL) chemotherapy.
Zdravilo Vectibix v kombinaciji s kemoterapijo z irinotekanom, bolusnim 5-fluorouracilom in levkovorinom(IFL).

An additional analysis of efficacy data by KRAS status did not identify a subset of patients who benefited from Vectibix in combination with oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
Dodatna analiza podatkov o učinkovitosti glede na stanje KRAS ni odkrila podskupine bolnikov, ki bi jim bil koristilo zdravilo Vectibix v kombinaciji s kemoterapijo na podlagi oksaliplatina ali irinotekana ter bevacizumab.

Vectibix in combination with oxaliplatin-based chemotherapy in patients with mutant RAS mCRC or for whom RAS tumour status is unknown.
Zdravilo Vectibix v kombinaciji s kemoterapijo na podlagi oksaliplatina pri bolnikih z mKRR z mutantnim RAS oz. bolnikih z mKRR, pri katerih stanje RAS tumorja ni znano.

Severe diarrhoea(NCI-CTC grade 3 and 4) was reported in 2% of patients treated with Vectibix as a monotherapy and in 17% of patients treated with Vectibix in combination with chemotherapy.
O hudi(3. in 4. stopnja po NCI-CTC) driski so poročali pri 2% bolnikov, zdravljenih z zdravilom Vectibix v monoterapiji, in pri 17% bolnikov, zdravljenjih z zdravilom Vectibix v kombinaciji s kemoterapijo.

The safety profile of Vectibix in combination with chemotherapy consisted of the reported adverse reactions of Vectibix(as a monotherapy) and the toxicities of the background chemotherapy regimen.
Varnostne značilnosti zdravila Vectibix v kombinaciji s kemoterapijo so obsegale poročila o neželenih učinkih zdravila Vectibix(kot monoterapije) in toksičnosti osnovne sheme kemoterapije.

In an interim analysis based on 947 randomized patients, shortened progression free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy.
Vmesna analiza na podlagi podatkov 947 randomiziranih bolnikov je pokazala krajši čas preživetja brez napredovanja in več smrti med bolniki, ki so dobivali Vectibix v kombinaciji z bevacizumabom in kemoterapijo.

Vectibix in combination with FOLFIRI has been investigated in a main study involving 1,186 patients who had been treated before, where Vectibix was compared with chemotherapy alone.
Zdravilo Vectibix so v kombinaciji s kemoterapijo FOLFIRI proučevali v glavni študiji, ki je zajela 1 186 bolnikov, ki so že bili zdravljeni, in ga primerjali s samostojno kemoterapijo.

Severe(NCI-CTC grade 3) skin reactions were reported in 34% and life-threatening(NCI-CTC grade 4) skin reactions in< 1% of patients who received Vectibix in combination with chemotherapy(n= 1,536).
Poročali so o hudih kožnih reakcijah(3. stopnja po NCI-CTC) pri 34% bolnikov in o življenjsko ogrožujočih kožnih reakcijah(4. stopnja po NCI-CTC) pri< 1% bolnikov, ki so prejemali zdravilo Vectibix v kombinaciji s kemoterapijo(n= 1.536).

Patients receiving Vectibix in combination with the IFL regimen[bolus 5-fluorouracil(500 mg/m2), leucovorin(20 mg/m2) and irinotecan(125 mg/m2)] experienced a high incidence of severe diarrhoea(see section 4.8).
Bolniki, ki so dobivali zdravilo Vectibix v kombinaciji z IFL shemo[bolus 5-fluorouracila(500 mg/m2), levkovorina(20 mg/m2) in irinotekana(125 mg/m2)], so zelo pogosto dobili hudo drisko(glejte poglavje 4.8).

A greater frequency of pulmonary embolism, infections(predominantly of dermatologic origin), diarrhoea, and dehydration was also observed in the treatment arms using Vectibix in combination with bevacizumab and chemotherapy.
V terapevtskih krakih z Vectibixom, uporabljenim v kombinaciji z bevacizumabom in kemoterapijo, so bile pogostejše tudi pljučna embolija, okužbe(pretežno dermatološkega izvora), driska in dehidracija.

Vectibix in combination with FOLFIRI has been investigated in a study involving 154 previously untreated patients which looked mainly at the percentage of patients who responded to treatment.
Zdravilo Vectibix so v kombinaciji s kemoterapijo FOLFIRI proučevali v študiji, ki je zajela 154 predhodno nezdravljenih bolnikov, opazovali pa so predvsem, kolikšen delež bolnikov se je odzval na zdravljenje.

In the fourth study, previously treated patients with wild-type RAS receiving Vectibix in combination with FOLFIRI lived for 16.2 months compared with 13.9 months in patients receiving FOLFIRI alone.
V četrti študiji so predhodno zdravljeni bolniki z divjim tipom gena RAS, ki so prejemali zdravilo Vectibix v kombinaciji s kemoterapijo FOLFIRI, živeli 16,2 meseca v primerjavi s 13,9 meseca pri bolnikih, ki so prejemali le kemoterapijo FOLFIRI.

The efficacy of Vectibix in combination with oxaliplatin, 5-fluorouracil(5-FU), and leucovorin(FOLFOX) was evaluated in a randomised, controlled trial of 1,183 patients with mCRC with the primary endpoint of PFS.
Učinkovitost zdravila Vectibix v kombinaciji z oksaliplatinom, 5-fluorouracilom(5-FU) in levkovorinom(FOLFOX) so ocenili v randomiziranem, kontroliranem preskušanju pri 1.183 bolnikih z mKRR, v katerem je bil primarni opazovani dogodek PFS.

Severe(NCI-CTC grade 3) skin reactions were reported in 34% and life-threatening(NCI- CTC grade 4) skin reactions in< 1% of patients who received Vectibix in combination with chemotherapy(n= 1536)(see section 4.8).
Poročali so o hudih kožnih reakcijah(3. stopnja po NCI-CTC) pri 34% bolnikov in o življenjsko ogrožujočih kožnih reakcijah(4. stopnja po NCI-CTC) pri< 1% bolnikov, ki so prejemali zdravilo Vectibix v kombinaciji s kemoterapijo(n= 1.536)(glejte poglavje 4.8).

The most increased serious adverse events were diarrhoea in patients treated with Vectibix in combination with either FOLFOX or FOLFIRI, and dehydration and pulmonary embolism when patients were treated with Vectibix in combination with FOLFIRI.
Pri bolnikih, ki so prejemali zdravilo Vectibix v kombinaciji s FOLFOX ali s FOLFIRI, se je najbolj povečala pojavnost resnega neželenega učinka diareje, pri bolnikih, ki so prejemali zdravilo Vectibix v kombinaciji s FOLFIRI pa dehidracija in pljučna embolija.

A greater frequency of pulmonary embolism, infections(predominantly of dermatologic origin), diarrhoea, electrolyte imbalances, nausea, vomiting and dehydration was also observed in the treatment arms using Vectibix in combination with bevacizumab and chemotherapy.
V terapevtskih krakih z zdravilom Vectibix, uporabljenim v kombinaciji z bevacizumabom in kemoterapijo, so bile pogostejše tudi pljučna embolija, okužbe(pretežno dermatološkega izvora), driska, neravnovesje elektrolitov, navzea, bruhanje in dehidracija.

In the first study, previously untreated patients with wild-type RAS receiving Vectibix in combination with FOLFOX lived for an average of 10.1 months without the disease getting worse compared with 7.9 months for patients receiving FOLFOX alone.
V prvi študiji so predhodno nezdravljeni bolniki z divjim tipom gena RAS prejemali zdravilo Vectibix v kombinaciji s kemoterapijo FOLFOX, pri čemer je bil čas preživetja teh bolnikov brez poslabšanja bolezni 10,1 meseca, v primerjavi s 7,9 meseca pri bolnikih, ki so bili zdravljeni le s kemoterapijo FOLFOX.

These include studies looking at the use of Vectibix in combination with other medicines, both in patients whose disease has been treated before and in patients who have not received any previous treatment for their cancer, as well as a study to confirm the effectiveness of Vectibix, given on its own, in its approved use.
Pri tem bodo vključene tudi študije uporabe zdravila Vectibix skupaj z drugimi zdravili pri bolnikih, pri katerih so bolezen zdravili že prej, in pri bolnikih, katerih rak še ni bil zdravljen, ter študija za potrditev učinkovitosti zdravila Vectibix, ki se daje samostojno v okviru odobrene uporabe.

Vectibix is used alone or in combination with other anticancer medicines.
Zdravilo Vectibix se uporablja samostojno ali v kombinaciji z drugimi zdravili proti raku.

Vectibix should not be administered in combination with IFL chemotherapy or with bevacizumab- containing chemotherapy.
Zdravila Vectibix se ne sme uporabljati v kombinaciji s kemoterapijo IFL ali kemoterapijo, ki vključuje bevacizumab.

Vectibix administered as a single agent or in combination with chemotherapy exhibits nonlinear pharmacokinetics.
Zdravilo Vectibix, aplicirano kot edino zdravilo ali v kombinaciji s kemoterapijo, ima nelinearno farmakokinetiko.

The efficacy of Vectibix in first-line in combination with FOLFIRI was evaluated in a single-arm study of 154 patients with the primary endpoint of objective response rate(ORR).
Učinkovitost zdravila Vectibix v prvi liniji zdravljenja v kombinaciji s FOLFIRI so ocenili v študiji z eno samo skupino pri 154 bolnikih, primarni opazovani dogodek pa je bil objektivni delež odziva(ORR).

Across all clinical trials, skin reactions occurred in 93% of patients receiving Vectibix as monotherapy or in combination with chemotherapy(n= 2,588).
V vseh kliničnih preskušanjih so se kožne reakcije pojavile pri 93% bolnikov, ki so prejemali zdravilo Vectibix v monoterapiji ali v kombinaciji s kemoterapijo(n= 2.588).